All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
ICML 2019 | What are the latest advances in the treatment of CLL?
Bookmark this article
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Michael Hallek from University Hospital of Cologne, Cologne, DE, about the latest advances in the treatment of chronic lymphocytic leukemia (CLL).
Michael Hallek describes that latest therapy options emerging from recent research, focusing on monotherapies with ibrutinib being potent first-line therapies, along with the strong move towards chemotherapy-free combinations.
He described these novel agents as venetoclax, ibrutinib, and obinutuzumab, and said that they need to be further investigated as to whether all three are needed, or if a particular pair or combination works better.
What are the latest advances in the treatment of CLL?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
44 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox